In a patient taking lorazepam (Ativan), trazodone, tizanidine (Zanaflex), and daridorexant who awakens about two hours after falling asleep, which medication should be tapered first to improve sleep?

Taper Lorazepam First

Lorazepam (Ativan) should be the first medication tapered in this patient, as benzodiazepines carry the highest risk of dependency, cognitive impairment, falls, and rebound insomnia, and guidelines strongly recommend against their use for chronic insomnia. 1

Rationale for Prioritizing Lorazepam Discontinuation

Benzodiazepines Are Strongly Contraindicated for Insomnia

• The VA/DoD and American Academy of Sleep Medicine guidelines issue strong recommendations against benzodiazepines for chronic insomnia due to high dependency risk, diversion potential, falls, cognitive impairment, and respiratory complications. 1, 2
• Benzodiazepines cause significant rebound insomnia upon withdrawal—in controlled studies, lorazepam 4 mg produced sleep latency increases of 60-77% above baseline and elevated total wake time during withdrawal nights 3 and 5. 3
• Lorazepam also causes rebound anxiety, severe hangover effects, anterograde amnesia, and impaired daytime functioning, particularly during the first 3 days of use. 3
• The harms of benzodiazepines substantially outweigh any sleep benefit despite demonstrated short-term efficacy. 1

Taper Protocol for Lorazepam

• Benzodiazepine hypnotics must be tapered gradually with concurrent CBT-I support—abrupt discontinuation worsens rebound phenomena. 4, 5
• Reduce the dose by 10-25% each week to minimize withdrawal symptoms and rebound insomnia. 5
• Multi-component CBT-I, daridorexant, eszopiclone, or melatonin 2 mg prolonged-release can facilitate cross-tapering when transitioning off benzodiazepines. 5

Why Not Taper the Other Medications First?

Trazodone Should Be Discontinued But Does Not Require Urgent Tapering

• Trazodone shows no improvement in sleep efficiency, sleep-onset latency, total sleep time, or wake after sleep onset compared to placebo in systematic reviews. 1, 2
• The VA/DoD guideline issues a "strong-against" recommendation for trazodone in chronic insomnia, citing low-quality evidence and an adverse-effect profile that outweighs limited benefits. 2
• Trazodone should be gradually reduced when discontinuing (not abruptly stopped), but it does not carry the same dependency, cognitive, or fall risks as lorazepam. 4
• Trazodone is not contributing to the patient's sleep maintenance problem (awakening 2 hours after sleep onset), making it a lower priority than lorazepam for immediate intervention.

Tizanidine (Zanaflex) Contributes to Sedation But Is Not a Primary Insomnia Agent

• Tizanidine causes dose-related sedation (48% of patients report sedation, 10% severe) and drowsiness that peaks 1.5 hours after dosing and can persist for 6 hours. 6
• Tizanidine is prescribed for muscle spasticity, not insomnia, so its discontinuation should be guided by the underlying indication rather than sleep optimization alone.
• If tizanidine is no longer medically necessary for spasticity, it can be tapered after lorazepam is discontinued, but it does not carry the same guideline-level contraindications for insomnia as benzodiazepines.

Daridorexant Should Be Continued

• Daridorexant (an orexin receptor antagonist) is recommended as a first-line pharmacologic option for insomnia with minimal dependence risk and is effective for sleep maintenance. 1, 2
• Daridorexant does not require tapering or special deprescribing protocols when discontinuation is needed. 4, 5
• This medication is appropriate for the patient's symptom pattern (awakening 2 hours after sleep onset suggests sleep maintenance insomnia), and there is no guideline-based reason to discontinue it.

Clinical Algorithm for This Patient

1. Begin tapering lorazepam immediately using a 10-25% weekly dose reduction schedule. 5
2. Initiate or reinforce CBT-I during the lorazepam taper to mitigate rebound insomnia and provide long-term benefit. 4, 5
3. Consider cross-tapering with daridorexant (already prescribed) or adding melatonin 2 mg prolonged-release to facilitate benzodiazepine discontinuation. 5
4. Discontinue trazodone gradually after lorazepam is fully tapered, as it provides no objective sleep benefit and carries unnecessary risks. 2, 4
5. Reassess tizanidine based on its primary indication (muscle spasticity)—if no longer needed, taper after the other medications are addressed.
6. Continue daridorexant as the evidence-based pharmacologic agent for sleep maintenance insomnia. 1, 2

Key Pitfalls to Avoid

• Never abruptly discontinue lorazepam—this will cause severe rebound insomnia, rebound anxiety, and potential withdrawal symptoms. 3, 5
• Do not assume trazodone is helping sleep—placebo-controlled trials show no objective benefit, and its continued use exposes the patient to unnecessary adverse effects. 1, 2
• Do not taper daridorexant—it is the only medication in this regimen with guideline support for chronic insomnia and does not require special discontinuation protocols. 1, 4, 5